Devonian Health Group, Inc. ( (TSE:GSD) ) has shared an update.
Devonian Health Group Inc. has announced the filing of a new patent application for the use of Thykamine™ as an antifibrotic agent. This application, supported by in vivo data, highlights the potential of thylakoid extracts in treating and slowing fibrosis progression, enhancing the therapeutic applications of Thykamine™. The filing aligns with Devonian’s broader strategy to expand its patent portfolio and solidify its position in the pharmaceutical industry, potentially impacting treatments for fibrotic diseases across various organs and tissues.
More about Devonian Health Group, Inc.
Devonian Health Group Inc. is a clinical stage pharmaceutical company that focuses on developing drugs for various autoimmune inflammatory conditions. The company specializes in creating novel therapeutic solutions and is known for its products like Thykamine™, which are part of their innovative SUPREX™ platform.
YTD Price Performance: 56.25%
Average Trading Volume: 29,790
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$37.06M
For detailed information about GSD stock, go to TipRanks’ Stock Analysis page.